QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) All Versions of this Article: jpet.106.101246v1 317/3/1134    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Dowling, M. R. Articles by Challiss, R. A. J. Search for Related Content PubMed PubMed Citation Articles by Dowling, M. R. Articles by Challiss, R. A. J.

CELLULAR AND MOLECULAR

A Single Point Mutation (N514Y) in the Human M₃ Muscarinic Acetylcholine Receptor Reveals Differences in the Properties of Antagonists: Evidence for Differential Inverse Agonism

Department of Cell Physiology and Pharmacology, University of Leicester, Leicester, United Kingdom (M.R.D., J.M.W., D.C.B., S.R.N., R.A.J.C.); and Novartis Horsham Research Centre, Horsham, West Sussex, United Kingdom (M.R.D., D.C.B., S.J.C.)

Received January 11, 2006; accepted February 16, 2006.

	Abstract

Top Abstract Materials and Methods Results Discussion References

 
A single asparagine-to-tyrosine point mutation in the human M muscarinic acetylcholine (mACh) receptor at residue 514 (N514Y) resulted in a marked increase (300%) in agonist-independent [³H]inositol phosphate ([³H]IP_x) accumulation compared with the response observed for the wild-type (WT) receptor. All the antagonists tested were able to inhibit both the WT-M₃ and ^N514YM₃ mACh receptor-mediated basal [³H]IP_x accumulation in a concentration-dependent manner. However, significant differences in both potency and binding affinity were only seen for those antagonists that possess greater receptor affinity. Despite being transfected with equivalent amounts of cDNA, cells expressed the ^N514YM₃ mACh receptor at levels that were only 25 to 30% of those seen for the WT receptor. Differences in the ability of chronic antagonist exposure to up-regulate ^N514YM₃ mACh receptor expression levels were also seen, with 4-diphenylacetoxy-N-methylpiperidine (4-DAMP) producing only 50% of the receptor up-regulation produced by atropine or pirenzepine. Basal phosphorylation of the ^N514YM₃ mACh receptor was approximately 100% greater than that seen for the WT-M₃ receptor. The ability of antagonists to decrease basal ^N514YM₃ mACh receptor phosphorylation revealed differences in inverse-agonist efficacy. Atropine, 4-DAMP, and pirenzepine all reduced basal phosphorylation to similar levels, whereas methoctramine, a full inverse agonist with respect to reducing agonist-independent [³H]IP_x accumulation, produced no significant attenuation of basal receptor phosphorylation. This study shows that mACh receptor inverse agonists can exhibit differential signaling profiles, which are dependent on the specific pathway investigated, and therefore provides evidence that the molecular mechanism of inverse agonism is likely to be more complex than the stabilization of a single inactive receptor conformation.

Recent studies where mutated human muscarinic acetylcholine (mACh) receptor subtypes have been expressed in recombinant cell lines have identified specific regions (Spalding et al., 1998) and single amino acid residues (Spalding et al., 1997) that seem to be important in maintaining the inactive conformation of the receptor and whose substitution(s) increase constitutive activity. These observations align with those from other receptors, which suggest that the activation process involves a specific rotation of receptor regions, particularly affecting the relative positions of the TM3 and TM6 domains (Farrens et al., 1996; Javitch et al., 1997). Although receptor-G protein contact sites are as yet poorly defined, it has been suggested that -helical cytoplasmic extensions of TM5 and TM6 may provide the surface for G protein interaction (Kristiansen, 2004) and that one function of the inactive receptor must be to prevent these activating domains from interacting with the G protein (Kristiansen, 2004). In support of this model, mutagenesis of the C-terminal end of the third intracellular loop in the human M₁ (Hoegger et al., 1995), rat M₃ (Schmidt et al., 2003), and human M₂ (Liu et al., 1996) mACh receptors have been shown to elicit constitutive activity.

In the present study, we have introduced a single point mutation (N514Y) into the human M₃ mACh receptor, homologous to that which generates constitutive activity in the M₅ mACh receptor (Spalding et al., 1997). The locus of this mutation is predicted to lie at the junction of TM6 and the third extracellular loop, and this substitution is predicted to mimic some of the movements involved in the receptor activation process leading to the cytoplasmic exposure of G protein binding domains. We show that the "inverse agonist" behavior of certain mACh antagonists is dependent on the functional assay used. Therefore, the assumption that inverse agonists operate by stabilizing a common inactive conformation of the receptor may be too simplistic.

	Materials and Methods

Top Abstract Materials and Methods Results Discussion References

 
Materials. 4-Diphenylacetoxy-N-methylpiperidine (4-DAMP), atropine, carbamylcholine (carbachol), GTP, methacholine (MCh), methoctramine, oxotremorine, pilocarpine, and poly-L-lysine were from Sigma-Aldrich (Poole, UK). Myo-[2-³H]inositol, N-methyl-[³H]scopolamine ([³H]NMS), [³²P]orthophosphate, and protein A-Sepharose were from Amersham Biosciences Ltd. (Chalfont St. Giles, UK). GeneJuice transfection reagent was from EMD Biosciences (Nottingham, UK). Human embryonic kidney (HEK)-293 cells and the M₃ antibody were a gift from Dr. A. B. Tobin (University of Leicester). All the cell culture reagents were from Invitrogen (Paisley, UK). All the other reagents were of analytical grade.

Mutagenesis and Expression. The M₃ mutant receptor was created using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) using the following primer and its complement: 5'-CCA TAC AAC ATC ATG GTT CTG GTA TAC ACC TTT TGT GAC AGC TGC-3'. Residues in bold encode both an amino acid residue for the N514Y substitution and a unique restriction site for AccI, which allowed for initial confirmation of successful mutagenesis before subsequent sequencing confirmation.

Transient Transfection of HEK-293 Cells. HEK-293 cells were grown in minimum Eagle's medium- supplemented with 10% fetal calf serum, 100 IU/ml penicillin, 100 µg/ml streptomycin, and 2.5 µg/ml amphotericin B. Cells were maintained at 37°C in 5% CO₂/humidified air. Transfections were performed on cells grown to 40 to 50% confluence using the transfection reagent GeneJuice (optimized at 1 µg of DNA/4 µl of GeneJuice) according to the manufacturer's protocol.

Membrane Preparation. Transfected HEK cells were grown to 70 to 80% confluence and briefly washed with ice-cold HEPES-buffered saline/EDTA (2 x 10 ml; 10 mM HEPES, 0.9% NaCl, and 0.2% EDTA, pH 7.4). All of the subsequent steps were conducted at 0–4°C. Cells were lifted from the flask with HEPES-buffered saline/EDTA. A cell pellet was recovered by centrifugation (250g for 5 min) and the pellet homogenized using a Polytron (PT2100; Kinematica AG, Littau/Lucerne, Switzerland) (20,000 rpm, 5 x 10-s bursts) in 10 mM HEPES and 10 mM EDTA, pH 7.4. The homogenate was centrifuged (50,000g, 20 min) and the pellet rehomogenized and centrifuged as described previously in a low EDTA buffer (10 mM HEPES and 0.1 mM EDTA, pH 7.4). The final pellet was suspended in this buffer at a concentration of 4 to 5 mg of protein/ml and stored at –80°C until required.

[³H]NMS Binding. A range of concentrations of [³H]NMS was used (0.07–3 nM) to construct saturation binding curves. Nonspecific binding was determined in the presence of 1 µM atropine. Transfected HEK cell membranes (10–20 µg) were incubated at room temperature for 90 min in assay buffer (10 mM HEPES and 1 mM MgCl₂, pH 7.4). Reactions were terminated by rapid vacuum filtration over Whatman GF/B filters and four washes with ice-cold assay buffer, and radioactivity on the filter was quantified by scintillation counting. Agonist and antagonist affinities were determined using membrane preparations (10–20 µg) from HEK cells expressing wild-type (WT)-M₃ or ^N514YM₃. Competition binding was performed in the presence of approximately 0.4 nM [³H]NMS for 2 h at 37°C.

Receptor Up-Regulation Studies. HEK-293 cells transfected with either WT-M₃ or ^N514YM₃ receptor were incubated with the indicated concentrations of antagonist for 24 h. At the end of this period, cells were washed rapidly with 3 x 1 ml of Krebs-Henseleit buffer (KHB) (118.6 mM NaCl, 4.7 mM KCl, 1.3 mM CaCl₂, 10 mM HEPES, 11.7 mM D-glucose, 1.2 mM MgSO₄, 1.2 mM KH₂PO₄, and 25 mM NaHCO₃, pH 7.4) and then incubated for 60 min at 37°C in 500 µl of KHB with approximately 5 nM [³H]NMS in the absence or presence of 1 µM atropine. Free radioligand was removed after transfer to ice by rapid washing of wells with 3 x 1 ml of ice-cold KHB. Cell monolayers were dissolved in 250 µl of 0.1 M NaOH, and radioactivity was determined.

[³H]Inositol Phosphate Accumulation. HEK-293 cells transfected with either WT-M₃ or ^N514YM₃ receptor were grown to 60 to 70% confluence and then labeled with 1 µCi/ml of myo-[2-³H]inositol for 24 h. Cell monolayers were washed and incubated in KHB at 37°C. For agonist additions, cells were incubated with LiCl (10 mM) for 15 min before agonist addition for a further 10 min. For inverse agonist additions, cells were incubated with the inverse agonist for 15 min before the addition of LiCl (10 mM), and incubations were continued for 10 min. In either case, incubations were terminated by rapid aspiration of buffer and addition of ice-cold trichloroacetic acid (0.5 M). The [³H] total inositol (poly)phosphate (IP_x) fraction was recovered exactly as described previously (Batty et al., 1997).

Quantification of M₃ mACh Receptor Phosphorylation. HEK-293 cells transfected with either WT-M₃ or ^N514YM₃ cDNA were grown to 80 to 90% confluence in six-well plates. Receptor phosphorylation was determined as described by Tobin (1997). Briefly, cells were incubated in phosphate-free KHB buffer containing [³²P]orthophosphate (50 µCi/ml) for 90 min at 37°C. The cells were either incubated with inverse agonists throughout the preincubation period or for 10 min in experiments with agonists. Incubations were terminated by aspiration and addition of ice-cold solubilization buffer (10 mM Tris, 10 mM EDTA, 500 mM NaCl, 0.2% SDS, 1% NP-40, 0.5% sodium deoxycholate, 0.2 mM sodium vanadate, and 2 mM disodium nitrophenyl phosphate, pH 7.4) for 30 min. Samples were centrifuged (14,000 rpm, 5 min, 4°C) and the supernatant incubated with M₃ antibody on ice for 60 min. The antibody-receptor complex was recovered by incubation with protein A-Sepharose for 1 h at 4°C. The protein A-Sepharose-bound complex was recovered by centrifugation (14,000 rpm, 1 min), and the beads were washed four times in Tris/EDTA buffer (10 mM Tris/HCl, 10 mM EDTA, pH 7.4). The final pellet was resuspended in 2x SDS-polyacrylamide gel electrophoresis sample buffer (10 mM Tris/HCl, pH 6.8, 200 mM dithiothreitol, 4% SDS, 0.1% bromphenol blue, and 20% glycerol) and incubated for 2 min at 85°C. Samples, equalized for receptor number (by [³H]NMS binding), were loaded onto an 8% SDS-polyacrylamide gel electrophoresis gel and run at 180 mV for 30 to 60 min. Radioactivity was visualized by autoradiography and scintillation counting.

Data and Statistical Analysis. Data are shown as mean ± S.E.M. for the indicated number of experiments. Saturation binding data were fitted with hyperbolae (one-site binding) using GraphPad Prism 3.0 (GraphPad Software, San Diego, CA). B_max and K_D values were derived from these curves. Competition binding curves and functional concentration-response curves were fitted to a four-parameter logistic equation using GraphPad Prism 3.0. The best fit between a variable Hill coefficient and a Hill coefficient fixed to unity was determined using an F-test. IC₅₀ values, generated by these inhibition curves, were corrected to give binding constant (K_i) values for each test compound using the Cheng-Prusoff equation (Cheng and Prusoff, 1973). The statistical significance of differences between data was determined using either Student's t test, with K_i and K_B values first being converted to the respective normally distributed negative logarithm (pK_i or pK_B) or one-way analysis of variance with Dunnett's post test for multiple comparisons.

	Results

Top Abstract Materials and Methods Results Discussion References

 
Characterization of mACh Receptor Populations Using [³H]NMS Binding. The HEK-293 cell clone used in this study possesses a small (B_max 34 ± 2 fmol/mg protein), endogenous M₃ mACh receptor population. Transient transfection of HEK cells with either WT-M₃ or ^N514YM₃ mACh receptor cDNA (20 µg/175-cm² flask) resulted in a marked increase in specific [³H]NMS binding sites (Fig. 1). Despite equal plasmid loading, the WT-M₃ mACh receptor was expressed at consistently higher (3-fold) densities than the ^N514YM₃ mutant receptor (see Fig. 1C). In addition, the K_D determined for [³H]NMS binding was significantly (p < 0.05) greater at the ^N514YM₃ receptor (269 ± 10 pM) than at the WT-M₃ receptor (169 ± 7 pM). In future experiments, receptor expression was adjusted to give approximately equal numbers of WT-M₃ or ^N514YM₃ mACh receptors, and individual K_D values were determined in each experiment to allow accurate determination of binding parameters (e.g., conversion of IC₅₀ to K_i values).

View larger version (15K): [in this window] [in a new window]   Fig. 1. [3H]NMS saturation binding to WT-M3 (A) or N514YM3 (B) mACh receptors in membranes prepared from HEK cells recombinantly expressing each receptor. Membranes were incubated with increasing concentrations (0–4 nM) [3H]NMS for 60 min at 37°C (see under Materials and Methods). Nonspecific binding was determined in the presence of 1 µM atropine. The Scatchard plot (C) shows the Bmax values achieved after transfection with cDNA (20 µg/175-cm2 flask) encoding either the WT-M3 or N514YM3 mACh receptor. All the experiments were performed in duplicate, and the graphs are representative of 12 to 14 separate experiments.

View larger version (23K): [in this window] [in a new window]   Fig. 2. Antagonist competition binding experiments on membranes prepared from HEK cells transiently expressing WT-M3 () or N514YM3 () mACh receptors. Membranes were incubated in the presence of 0.3 to 0.5 nM [3H]NMS and the indicated concentrations of atropine (A), 4-DAMP (B), pirenzepine (C), or methoctramine (D) for 60 min at 37°C (see under Materials and Methods). Data shown represent the mean ± S.E.M. from at least three experiments performed in duplicate.

These data suggest that atropine and 4-DAMP are behaving as inverse agonists at the ^N514YM₃ mACh receptor. If the N514Y mutation has induced a degree of agonist-independent G protein coupling, then it may be possible to detect a greater difference in inverse agonist affinities between WT and ^N514YM₃ receptors if the proportion of uncoupled receptors is increased, provided there is sufficient G protein available in the system (Strange, 2002). This has been tested by supplementing the binding assay buffer with GTP (100 µM); under these conditions, no additional effects on pIC₅₀ values were observed for any of the inverse agonist/antagonists studied here (data not shown).

The effect of the N514Y mutation on agonist binding affinity was also assessed (Fig. 3). Both MCh and pilocarpine exhibited significantly higher apparent binding affinities at the ^N514YM₃ compared with the WT-M₃ mACh receptor (pK_B values: WT, 4.89 ± 0.07; N514Y, 6.01 ± 0.06 for MCh; p < 0.005; WT, 5.47 ± 0.04; N514Y, 6.16 ± 0.06 for pilocarpine; p < 0.005). Again, inclusion of GTP (100 µM) did not affect apparent affinity estimates for either MCh or pilocarpine (data not shown).

View larger version (18K): [in this window] [in a new window]   Fig. 3. Agonist competition binding experiments on membranes prepared from HEK cells transiently expressing WT-M3 () or N514YM3 () mACh receptors. Membranes were incubated in the presence of 0.3 to 0.5 nM [3H]NMS and the indicated concentrations of MCh (A) or pilocarpine (B) for 60 min at 37°C (see under Materials and Methods). Data shown represent the mean ± S.E.M. from at least three experiments performed in duplicate.

Effects of mACh Receptor Inverse Agonist/Antagonists on [³H]IP_x Accumulation. To examine the effects of receptor mutation on the ability to activate a G protein-dependent signaling output, [³H]IP_x accumulation in intact HEK cells was assessed. Transfection of cells with ^N514YM₃ mACh receptor cDNA (0.5 µg) resulted in a B_max value of 1140 ± 80 fmol/mg protein. In contrast, a higher maximal receptor expression level could be obtained for the WT-M₃ receptor (B_max 3210 ± 159 fmol/mg protein). Therefore, HEK cells were routinely transfected with 0.5 µg of N514Y mutant receptor cDNA or an amount of WT-M₃ cDNA that would result in a similar receptor expression level (typically 0.15 µg). In each experiment, the matching of mACh receptor expression levels was checked using [³H]NMS binding. The addition of Li⁺ (10 mM) to HEK cells expressing ^N514YM₃, but not WT-M₃, mACh receptors caused a near-linear increase in [³H]IP_x accumulation such that after only 10 min of Li⁺ addition, [³H]IP_x accumulation was approximately 300% higher in the ^N514YM₃ receptor-expressing cells. It should be noted that although stimulation of the small, endogenous M₃ mACh receptor population generated a measurable [³H]IP_x response in the presence of Li⁺, this was small (typically <25% of that seen in transfected cells). Nevertheless, empty vector-transfected HEK cells were always included to assess any potential influence of the endogenous receptor population.

To assess inverse agonism, HEK cells expressing either ^N514YM₃ or WT-M₃ mACh receptors were incubated with atropine, 4-DAMP, pirenzepine, or methoctramine for 15 min before Li⁺ addition for a further 10 min (Fig. 4). All the agents behaved as inverse agonists concentration-dependently decreasing [³H]IP_x accumulation in the presence of Li⁺ to levels observed in the absence of Li⁺. These data suggest that all four antagonists behave as "full inverse agonists" with respect to the M₃ mACh receptor coupling to phosphoinositide hydrolysis. Comparison of half-maximal inhibitory concentrations revealed that whereas pirenzepine and methoctramine exhibited no significant differences in their IC₅₀ values with respect to decreasing basal [³H]IP_x accumulation via WT-M₃ or ^N514YM₃ mACh receptors, atropine (pIC₅₀, WT, 8.84 ± 0.08; N514Y, 8.26 ± 0.02) and 4-DAMP (pIC₅₀, WT, 8.73 ± 0.02; N514Y, 8.39 ± 0.01) showed significant (3.8- and 2.2-fold, respectively) differences (p < 0.05).

View larger version (23K): [in this window] [in a new window]   Fig. 4. Inverse agonist effects of mACh receptor antagonists on basal phosphoinositide hydrolysis in HEK cells expressing either the WT-M3 () or N514YM3 () receptor. HEK cell monolayers were incubated for 15 min with the indicated concentrations of atropine (A), 4-DAMP (B), pirenzepine (C), or methoctramine (D) before the addition of 10 mM Li+ and the continuation of incubations for a further 10 min. Data are shown as mean ± S.E.M. from at least three separate experiments performed in duplicate.

View larger version (19K): [in this window] [in a new window]   Fig. 5. Agonist-stimulated increases in phosphoinositide hydrolysis in HEK cells expressing either the WT-M3 (A) or N514YM3 (B) mACh receptor. HEK cell monolayers were incubated for 15 min in the presence of 10 mM Li+. The indicated concentrations of MCh, oxotremorine, or pilocarpine were then added and incubations continued for a further 10 min. Data are shown as mean ± S.E.M. from at least three separate experiments performed in duplicate.

View larger version (26K): [in this window] [in a new window]   Fig. 6. Effects of chronic (24 h) treatment of HEK cells with putative inverse agonists on the expression levels of either the WT-M3 or N514YM3 mACh receptor. HEK cells were transfected with either WT-M3 or N514YM3 cDNA (0.2 µg of DNA/well). After 24 h, the indicated concentrations of inverse agonist were added and the incubation continued for 24 h. HEK cell monolayers were then washed thoroughly in KHB, and a single concentration (5 nM) of [3H]NMS was added to establish a Bmax value (see under Materials and Methods). A, the concentration-dependent increases in N514YM3 mACh receptor expression are shown for 24-h preincubations with atropine, pirenzepine, or 4-DAMP. A (inset), the time course of increases in receptor expression elicited by each inverse agonist. The inset also shows that atropine fails to cause any change in the receptor expression level in HEK cells transfected with WT-M3. B, the effects of a 24-h pretreatment with atropine (1 µM), 4-DAMP (1 µM), or pirenzepine (10 µM) on endogenous and WT-M3 mACh receptor expression levels. In all the cases, data are shown as mean ± S.E.M. for at least three experiments performed in duplicate.

The agonist-mediated receptor up-regulation of the ^N514YM₃ receptor by atropine, pirenzepine, and 4-DAMP appeared to occur linearly over the 24-h incubation period (Fig. 6A, inset). In addition, cell surface expression of either the endogenous M₃ mACh receptor population in HEK cells or the recombinant WT-M₃ receptor was unaffected by 24-h incubations with any of these agents (see Fig. 6B).

Effects of Inverse Agonists on Phosphorylation of the Wild-Type and N514Y Mutant M₃ mACh Receptor. ³²P_i labeling of HEK cells has allowed basal and agonist-stimulated WT-M₃ and ^N514YM₃ mACh receptor phosphorylation to be assessed. Basal phosphorylation of the ^N514YM₃ receptor was 50 to 60% greater than for the WT-M₃ receptor (WT, 8304 ± 412; N514Y, 12,898 ± 496 absorbance units/mm²; p < 0.01; Fig. 7). Despite the increased basal receptor phosphorylation, MCh (1 mM) caused similar maximal increases in phosphorylation of the WT-M3 and ^N514YM₃ mACh receptors (Fig. 7B). Inclusion of atropine (1 µM present throughout the ³²P_i labeling period) had no effect on WT-M₃ receptor phosphorylation but significantly reduced phosphorylation of the ^N514YM₃ mACh receptor phosphorylation (by 56 ± 6%; p < 0.01; see Fig. 7B). These data indicate that the ^N514YM₃ mACh receptor exhibits constitutive phosphorylation that can be suppressed to WT-M₃ receptor basal phosphorylation levels by an inverse agonist.

View larger version (34K): [in this window] [in a new window]   Fig. 7. Comparison of agonist and inverse agonist stimulation on WT-M and N514YM3 mACh receptor phosphorylation. HEK cells transfected with either WT-M3 or N514YM3 cDNA were loaded with 32Pi for 60 min at 37°C in the presence or absence of atropine (1 µM). Where indicated, MCh (1 mM) was added for 10 min after the 60-min labeling period in the absence of atropine. Samples were processed to determine levels of M3 mACh receptor phosphorylation as described under Materials and Methods. A, a representative autoradiogram, and B shows quantified data as mean ± S.E.M. collected from four separate experiments performed in duplicate. Statistical significance is indicated as **, p < 0.01 for basal N514YM3 versus WT-M3 phosphorylation; ##, p < 0.01 for an atropine-induced decrease in basal WT-M3 phosphorylation.

Like atropine, 4-DAMP (1 µM) and pirenzepine (10 µM) also significantly reduced the constitutive phosphorylation of the ^N514YM₃ mACh receptor (Fig. 8). In contrast, methoctramine (100 µM), a full inverse agonist with respect to constitutive [³H]IP_x accumulation, failed significantly to affect constitutive ^N514YM₃ receptor phosphorylation (Fig. 8). Unfortunately, the technically demanding nature of these experiments precluded concentration dependencies for the effects of the inverse agonists being established.

View larger version (40K): [in this window] [in a new window]   Fig. 8. Comparison of the inverse agonist activities of mACh receptor antagonists with respect to decreasing basal receptor phosphorylation. HEK cells transfected with N514YM3 cDNA were loaded with 32Pi for 60 min at 37°C in the presence or absence of atropine (1 M), pirenzepine (pirenz, 10 µM), 4-DAMP (1 µM), or methoctramine (methoc, 100 µM). The effect of agonist stimulation (MCh, 1 mM) was also assessed by addition of this agent for 10 min after the 60-min 32Pi labeling period. Samples were processed to determine levels of N514YM3 mACh receptor phosphorylation as described under Materials and Methods. A, a representative autoradiogram, and B shows quantified data as mean ± S.E.M. collected from four separate experiments performed in duplicate. Statistical significance is indicated as *, p < 0.05 for a decrease in basal receptor phosphorylation in the presence of the inverse agonist; **, p < 0.01 for a stimulatory effect of MCh on the level of N514YM3 mACh receptor phosphorylation.

	Discussion

Top Abstract Materials and Methods Results Discussion References

Antagonist binding profiles showed that only mACh antagonists with relatively high affinity for the WT-M₃ receptor exhibited a significant decrease in binding affinity for the mutant ^N514YM₃ receptor. A decrease in inverse agonist affinity is predicted if it is assumed that the N514Y mutation induces a conformation that (at least partially) resembles the active state of the receptor and that the inverse agonist preferentially binds to the inactive (R) state of the receptor (de Ligt et al., 2000; Strange, 2002). Compared with the increases in agonist affinity observed for the mutant receptor, the reductions in antagonist affinity are modest. However, it has been shown that a 2-fold reduction in inverse agonist apparent affinity is predicted for a constitutively active mutant in which 50% of receptors are in the active (R*) state (relative to no detectable constitutive activity in the WT receptor) (Wade et al., 2001). The lack of affinity differences seen for pirenzepine and methoctramine may indicate that these compounds exert their inverse agonism via a mechanism distinct from a stabilization of R. Support for this idea comes from the observation that although all the inverse agonists examined here inhibited agonist-independent [³H]IP_x accumulation to similar extents, pEC₅₀ values for the ^N514YM₃ were significantly reduced, relative to the WT-M₃ receptor, for atropine and 4-DAMP but not for pirenzepine or methoctramine.

One mode of inverse agonist action, which allows an inverse agonist to suppress basal activity, but not exhibit a decreased affinity at a constitutively active mutant receptor, has recently been proposed (Strange, 2002). This does not involve a redistribution of receptor states but one in which the inverse agonist switches the active conformation of the receptor to an inactive state that still retains the ability to bind and sequester G proteins but is unable to activate them (McLoughlin and Strange, 2000; Strange, 2002; Monczor et al., 2003). A species of receptor that is inactive but still binds G protein is one of the key features of the cubic ternary complex model (Weiss et al., 1996) and one that distinguishes it from the extended ternary complex model.

At equivalent plasmid loading, the cell-surface expression level of the ^N514YM₃ mACh receptor was approximately 3-fold lower than that for the WT-M₃ receptor. The ^N514YM₃ (but not the WT-M₃) receptor expression level could be significantly increased by chronic (24 h) incubation in the presence of an inverse agonist. Ligand-mediated receptor up-regulation has been reported previously for constitutively active mutant receptors (Smit et al., 1996; Stevens et al., 2000; Li et al., 2001; Pauwels and Tardif, 2002), although the precise molecular mechanisms involved are still debated (Parnot et al., 2002). For some CAM-GPCR, the degree of up-regulation is positively correlated with both the degree of constitutive activity in the system and the ability of a ligand to decrease basal activity. The up-regulation of a CAM H₂ histamine receptor has been shown by preincubation with ligands, such as cimetidine and ranitidine, which were characterized as inverse agonists by their ability to decrease basal and forskolin-induced cyclic AMP production. Burimamide, which behaved as a neutral antagonist in cyclic AMP assays, did not affect the level of the H₂ histamine receptor expression (Smit et al., 1996). This suggests that the receptor may be down-regulated as a consequence of productive G protein coupling. If a CAM-GPCR functions in a similar way to its cognate agonist-induced WT counterpart, it would follow that only inverse agonists would cause up-regulation by virtue of stabilizing the inactive conformation (Parnot et al., 2002). However, other studies (Gether et al., 1997; Pauwels and Tardif, 2002) have shown that the creation of a CAM can diminish stabilizing constraints within the receptor, leading to an inherently unstable receptor that is more susceptible to destabilization and/or proteolytic degradation (Stevens et al., 2000). In this case, the expression level of the mutant is increased by any ligand [(inverse) agonist/antagonist] regardless of its efficacy.

In this study, three of the antagonists, classified as inverse agonists from their ability to decrease basal [³H]IP_x accumulation, up-regulated the expression of the ^N514YM₃ receptor in a time- and concentration-dependent manner. This effect was specific to the ^N514YM₃ receptor because no significant effect on the receptor density could be detected for either the recombinant WT-M₃ or endogenous HEK-M₃ receptor population. Despite being a full inverse agonist in [³H]IP_x assays, 4-DAMP was only 50% as efficacious as atropine with respect to ^N514YM₃ receptor up-regulation. It is noteworthy that 4-DAMP possesses a permanent positive charge, which is likely to reduce its membrane permeability. It has been shown that membrane-permeable ligands are able to facilitate the endoplasmic reticulum export of the -opioid receptor to the cell surface by acting as molecular "chaperones" (Petaja-Repo et al., 2002). Thus, up-regulation of a CAM µ-opioid receptor by naloxone methiodide (which, like 4-DAMP, possesses a permanent positive charge) was only 50% as efficacious as naloxone (Li et al., 2001). It is possible that in the ^N514YM₃-HEK system inverse agonists increase cell surface receptor expression by increasing both receptor stability and facilitating export of the CAM receptor through its intracellular processing pathway. Therefore, the lower efficacy of 4-DAMP may result from its inability to cross the lipid membrane and to facilitate this process. Up-regulation, by both antagonists and agonists of a constitutively active chimeric M₃ mACh receptor, has also been reported (Zeng et al., 2003). This study showed that inverse agonist-mediated inhibition of proteosomal degradation of the CAM receptor is one potential mechanism involved in up-regulation. Interestingly, this study also showed a correlation between ligand binding affinity and receptor up-regulation for all the compounds tested, except 4-DAMP. The authors suggested that one possible reason for this discrepancy was that 4-DAMP is unstable in aqueous solution. However, we have found no decrease in 4-DAMP apparent binding affinity under the conditions used here (data not shown); therefore, the reason for the behavior of 4-DAMP remains unclear.

The M₃ mACh receptor has been shown to be phosphorylated in response to agonist stimulation by a variety of protein kinases, including GPCR kinases (Willets et al., 2003) The observation that the ^N514YM₃ mutant is significantly more phosphorylated than the WT-M₃ suggests that the CAM receptor may adopt a conformation more closely resembling that of the agonist-bound WT-M₃ receptor. The human M₃ receptor possesses a large number of potential serine/threonine phospho-acceptor sites (>50 in the i3 loop alone), and we presently have no information on whether the increased basal phosphorylation of ^N514M₃ is at similar or different sites to those modified during agonist-dependent phosphorylation.

The increased basal phosphorylation of the ^N514YM₃ mACh receptor raises the intriguing possibility that this mutant receptor is also constitutively desensitized, and consequently, the observed degree of constitutive activity may well be underestimated. Quantification of the extent to which atropine, 4-DAMP, pirenzepine, and methoctramine decrease basal ^N514YM₃ phosphorylation also revealed differences with respect to the behaviors of these inverse agonists as suppressors of [³H]IP_x accumulation. Thus, methoctramine, which was a full inverse agonist in the latter assay, failed significantly to attenuate basal phosphorylation of the ^N514YM₃ receptor. Recent evidence obtained for the AT_1A (Thomas et al., 2000) and µ-opioid (Yu et al., 1997) receptors has shown that G protein coupling and receptor phosphorylation and internalization are not necessarily a sequential series of events and that some agonists are able to induce receptor phosphorylation and/or internalization without detectable G protein coupling. "Ensemble theory" (Kenakin and Onaran, 2002) suggests that the behavior of each GPCR involves the stabilization of a microconformation and that the unique selective affinity of a ligand changes the redistribution of receptor conformations to initiate or inhibit a response. Therefore, it is possible that methoctramine stabilizes conformation(s) of the ^N514YM₃ receptor that inhibit G protein coupling but are still constitutively phosphorylated.

In summary, the ^N514YM₃ mACh receptor is an interesting CAM for pharmacological analysis because it displays classic hallmarks of constitutive activity, including 1) increased agonist-independent PLC activity, which is concentration-dependently inhibited by inverse agonists, 2) decreased receptor stability/expression that can be rescued by inverse agonists, 3) increased agonist efficacy and affinity and decreased antagonist affinity, and 4) increased levels of "basal" receptor phosphorylation. Although all the antagonists studied here can be classified as full inverse agonists based on their ability to decrease agonist-independent [³H]IP_x accumulation, we have found interesting differences in the pharmacology of these compounds when receptor expression levels and receptor phosphorylation responses were examined.

	Acknowledgements

 
We thank Dr. A. B. Tobin (University of Leicester) for providing the human M₃ mACh receptor polyclonal antibody and for constructive input to various aspects of this project.

	Footnotes

 
We thank Novartis Pharma Research for funding a studentship for M.R.D. This work was also supported by a program grant (062495) from the Wellcome Trust of Great Britain.

doi:10.1124/jpet.106.101246.

ABBREVIATIONS: GPCR, G protein-coupled receptor; mACh, muscarinic acetylcholine; 4-DAMP, 4-diphenylacetoxy-N-methylpiperidine; MCh, methacholine; NMS, N-methyl scopolamine; HEK, human embryonic kidney; WT, wild type; KHB, Krebs-Henseleit buffer; IP_x, total inositol (poly)phosphate fraction; CAM, constitutively active mutant.

Address correspondence to: R. A. J. Challiss, Department of Cell Physiology and Pharmacology, Maurice Shock Medical Sciences Building, University of Leicester, University Road, Leicester, LE1 9HN, UK. E-mail: jc36{at}leicester.ac.uk

	References

Top Abstract Materials and Methods Results Discussion References

 

Batty IH, Carter AN, Challiss RAJ, and Hawthorne JN (1997) Receptor-linked phosphoinositide metabolism, in Neurochemistry—A Practical Guide (Turner AJ and Bachelard H eds) ed 2, pp 229–268, IRL Press, Oxford.

Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K₁) and the concentration of inhibitor which causes 50 per cent inhibition (I₅₀) of an enzymatic reaction. Biochem Pharmacol 22: 3099–3108.[CrossRef][Medline]

Costa T and Herz A (1989) Antagonists with negative intrinsic activity at opioid receptors coupled to GTP-binding proteins. Proc Natl Acad Sci USA 86: 7321–7325.[Abstract/Free Full Text]

de Ligt RA, Kourounakis AP, and IJzerman AP (2000) Inverse agonism at G protein-coupled receptors: (patho)physiological relevance and implications for drug discovery. Br J Pharmacol 130: 1–12.[CrossRef][Medline]

Farrens DL, Altenbach C, Yang K, Hubbell WL, and Khorana HG (1996) Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin. Science (Wash DC) 274: 768–770.[Abstract/Free Full Text]

Ford DJ, Essex A, Spalding TA, Burstein ES, and Ellis J (2002) Homologous mutations near the junction of the sixth transmembrane domain and the third extracellular loop lead to constitutive activity and enhanced agonist affinity at all muscarinic receptor subtypes. J Pharmacol Exp Ther 300: 810–817.[Abstract/Free Full Text]

Gether U, Ballesteros JA, Seifert R, Sanders-Bush E, Weinstein H, and Kobilka BK (1997) Structural instability of a constitutively active G protein-coupled receptor. Agonist-independent activation due to conformational flexibility. J Biol Chem 272: 2587–2590.[Abstract/Free Full Text]

Hoegger P, Shockley MS, Lameh J, and Sadee W (1995) Activating and inactivating mutations in N- and C-terminal i3 loop junctions of muscarinic acetylcholine Hm1 receptors. J Biol Chem 270: 7405–7410.[Abstract/Free Full Text]

Huang XP, Williams FE, Peseckis SM, and Messer WS (1999) Differential modulation of agonist potency and receptor coupling by mutations of Ser388Tyr and Thr389Pro at the junction of transmembrane domain VI and the third extracellular loop of human M₁ muscarinic acetylcholine receptor. Mol Pharmacol 56: 775–783.[Abstract/Free Full Text]

Javitch JA, Fu D, Liapakis G, and Chen J (1997) Constitutive activation of the ₂ adrenergic receptor alters the orientation of its sixth membrane-spanning segment. J Biol Chem 272: 18546–18549.[Abstract/Free Full Text]

Kenakin T and Onaran O (2002) The ligand paradox between affinity and efficacy: can you be there and not make a difference? Trends Pharmacol Sci 23: 275–280.[CrossRef][Medline]

Kjelsberg MA, Cotecchia S, Ostrowski J, Caron MG, and Lefkowitz RJ (1992) Constitutive activation of the _1B-adrenergic receptor by all amino acid substitutions at a single site. Evidence for a region which constrains receptor activation. J Biol Chem 267: 1430–1433.[Abstract/Free Full Text]

Kristiansen K (2004) Molecular mechanisms of ligand binding, signaling and regulation within the superfamily of G protein-coupled receptors: molecular modeling and mutagenesis approaches to receptor structure and function. Pharmacol Ther 103: 21–80.[CrossRef][Medline]

Lee NH and El-Fakahany EE (1991) Allosteric interactions at the m1, m2 and m3 muscarinic receptor subtypes. J Pharmacol Exp Ther 256: 468–479.[Abstract/Free Full Text]

Leff P (1995) The two-state model of receptor activation. Trends Pharmacol Sci 16: 89–97.[CrossRef][Medline]

Li J, Chen C, Huang P, and Liu-Chen LY (2001) Inverse agonist up-regulates the constitutively active D3.49(164)Q mutant of the rat µ-opioid receptor by stabilizing the structure and blocking constitutive internalization and down-regulation. Mol Pharmacol 60: 1064–1075.[Abstract/Free Full Text]

Liu J, Blin N, Conklin BR, and Wess J (1996) Molecular mechanisms involved in muscarinic acetylcholine receptor-mediated G protein activation studied by insertion mutagenesis. J Biol Chem 271: 6172–6178.[Abstract/Free Full Text]

McLoughlin DJ and Strange PG (2000) Mechanisms of agonism and inverse agonism at serotonin 5-HT_1A receptors. J Neurochem 74: 347–357.[CrossRef][Medline]

Milligan G (2003) Constitutive activity and inverse agonists of G protein-coupled receptors: a current perspective. Mol Pharmacol 64: 1271–1276.[Abstract/Free Full Text]

Monczor F, Fernandez N, Legnazzi BL, Riveiro ME, Baldi A, Shayo C, and Davio C (2003) Tiotidine, a histamine H₂ receptor inverse agonist that binds with high affinity to an inactive G-protein-coupled form of the receptor. Experimental support for the cubic ternary complex model. Mol Pharmacol 64: 512–520.[Abstract/Free Full Text]

Parnot C, Miserey-Lenkei S, Bardin S, Corvol P, and Clauser E (2002) Lessons from constitutively active mutants of G protein-coupled receptors. Trends Endocrinol Metab 13: 336–343.[CrossRef][Medline]

Pauwels PJ and Tardif S (2002) Enhanced stability of wild-type and constitutively active _2A-adrenoceptors by ligands with agonist, silent and inverse agonist properties. Naunyn-Schmiedeberg's Arch Pharmacol 366: 134–141.[Medline]

Petaja-Repo UE, Hogue M, Bhalla S, Laperriere A, Morello JP, and Bouvier M (2002) Ligands act as pharmacological chaperones and increase the efficiency of -opioid receptor maturation. EMBO (Eur Mol Biol Organ) J 21: 1628–1637.[CrossRef][Medline]

Samama P, Cotecchia S, Costa T, and Lefkowitz RJ (1993) A mutation-induced activated state of the ₂-adrenergic receptor. Extending the ternary complex model. J Biol Chem 268: 4625–4636.[Abstract/Free Full Text]

Samama P, Pei G, Costa T, Cotecchia S, and Lefkowitz RJ (1994) Negative antagonists promote an inactive conformation of the ₂-adrenergic receptor. Mol Pharmacol 45: 390–394.[Abstract]

Schmidt C, Li B, Bloodworth L, Erlenbach I, Zeng FY, and Wess J (2003) Random mutagenesis of the M₃ muscarinic acetylcholine receptor expressed in yeast. Identification of point mutations that "silence" a constitutively active mutant M₃ receptor and greatly impair receptor/G protein coupling. J Biol Chem 278: 30248–30260.[Abstract/Free Full Text]

Smit MJ, Leurs R, Alewijnse AE, Blauw J, Van Nieuw Amerongen GP, Van De Vrede Y, Roovers E, and Timmerman H (1996) Inverse agonism of histamine H₂ antagonist accounts for upregulation of spontaneously active histamine H₂ receptors. Proc Natl Acad Sci USA 93: 6802–6807.[Abstract/Free Full Text]

Spalding TA, Burstein ES, Henderson SC, Ducote KR, and Brann MR (1998) Identification of a ligand-dependent switch within a muscarinic receptor. J Biol Chem 273: 21563–21568.[Abstract/Free Full Text]

Spalding TA, Burstein ES, Wells JW, and Brann MR (1997) Constitutive activation of the m5 muscarinic receptor by a series of mutations at the extracellular end of transmembrane 6. Biochemistry 36: 10109–10116.[CrossRef][Medline]

Stevens PA, Bevan N, Rees S, and Milligan G (2000) Resolution of inverse agonist-induced up-regulation from constitutive activity of mutants of the _1b-adrenoceptor. Mol Pharmacol 58: 438–448.[Abstract/Free Full Text]

Strange PG (2002) Mechanisms of inverse agonism at G-protein-coupled receptors. Trends Pharmacol Sci 23: 89–95.[CrossRef][Medline]

Thomas WG, Qian H, Chang CS, and Karnik S (2000) Agonist-induced phosphorylation of the angiotensin II (AT_1A) receptor requires generation of a conformation that is distinct from the inositol phosphate-signaling state. J Biol Chem 275: 2893–2900.[Abstract/Free Full Text]

Tobin AB (1997) Protocols employed in the investigation of G protein-coupled receptor phosphorylation. Methods Mol Biol 83: 227–234.[Medline]

Wade SM, Lan K, Moore DJ, and Neubig RR (2001) Inverse agonist activity at the _2A-adrenergic receptor. Mol Pharmacol 59: 532–542.[Abstract/Free Full Text]

Weiss JM, Morgan PH, Lutz MW, and Kenakin TP (1996) The cubic ternary complex model. I. model description. J Theor Biol 178: 151–167.

Willets JM, Mistry R, Nahorski SR, and Challiss RA (2003) Specificity of G protein-coupled receptor kinase 6-mediated phosphorylation and regulation of single-cell m3 muscarinic acetylcholine receptor signaling. Mol Pharmacol 64: 1059–1068.[Abstract/Free Full Text]

Yu Y, Zhang L, Yin X, Sun H, Uhl GR, and Wang JB (1997) Mu opioid receptor phosphorylation, desensitization and ligand efficacy. J Biol Chem 272: 28869–28874.[Abstract/Free Full Text]

Zeng FY, McLean AJ, Milligan G, Lerner M, Chalmers DT, and Behan DP (2003) Ligand specific up-regulation of a Renilla reniformis luciferase-tagged, structurally unstable muscarinic M₃ chimeric G protein-coupled receptor. Mol Pharmacol 64: 1474–1484.[Abstract/Free Full Text]

This Article Abstract Full Text (PDF) All Versions of this Article: jpet.106.101246v1 317/3/1134    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Dowling, M. R. Articles by Challiss, R. A. J. Search for Related Content PubMed PubMed Citation Articles by Dowling, M. R. Articles by Challiss, R. A. J.